UPDATE: Baird Upgrades athenahealth, Inc. to Outperform

Eric Coldwell, analyst at Baird, on Tuesday upgraded athenahealth, Inc. from Neutral to Outperform with a price target of $255. In the short term, the analyst at Baird, “would love to see a pullback” and said he is “not saying ATHN has to be bought right here, right now.” Instead Coldwell